

<b>Statistical analysis title</b>	Cohort 1, ACP: Fesoterodine 4 mg
Statistical analysis description	P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline number of micturitions and catheterisations combined per 24 hours and baseline weight.
Comparison groups	Cohort 1, Active Comparator Phase: Fesoterodine 4 mg
Number of subjects included in analysis	41
Analysis specification	Pre-specified
Analysis type	Superiority
P-value	= 0.0111
Method	ANCOVA
Confidence interval	
<b>Statistical analysis title</b>	Cohort 1, ACP: Fesoterodine 8 mg
Statistical analysis description	P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline number of micturitions and catheterisations combined per 24 hours and baseline weight.
Comparison groups	Cohort 1, Active Comparator Phase: Fesoterodine 8 mg

Number of subjects included in analysis	37
Analysis specification	Pre-specified
Analysis type	Superiority
P-value	= 0.0171
Method	ANCOVA
Confidence interval	
<b>Statistical analysis title</b>	Cohort 1, ACP: Oxybutynin
Statistical analysis description	P-value was calculated for change from Baseline at Week 12, based on an ANCOVA model with terms for treatment group, baseline number of micturitions and catheterisations combined per 24 hours and baseline weight.
Comparison groups	Cohort 1, Active Comparator Phase: Oxybutynin
Number of subjects included in analysis	38
Analysis specification	Pre-specified
Analysis type	Superiority
P-value	= 0.0028

Method	ANCOVA
Confidence interval	